HUA E YU

Summary

Affiliation: City of Hope National Medical Center
Country: USA

Publications

  1. ncbi request reprint Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
    Hua Yu
    Division of Cancer Immunotherapeutics and Tumour Immunology, Beckman Research Institute at the City of Hope National Medical Center, Duarte, California 91010, USA
    Nat Rev Immunol 7:41-51. 2007
  2. pmc IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway
    Lin Wang
    Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute at City of Hope Medical Center, Duarte, CA 91010, USA
    J Exp Med 206:1457-64. 2009
  3. pmc In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
    Marcin Kortylewski
    Department of Cancer Immunotherapeutics, Beckman Research Institute at City of Hope, Duarte, California, USA
    Nat Biotechnol 27:925-32. 2009
  4. pmc STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
    Heehyoung Lee
    Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Nat Med 16:1421-8. 2010
  5. pmc Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma
    Shasha Li
    Genetic Engineering International Cooperation Base of Chinese Ministry of Science and Technology, Key Laboratory of Molecular Biophysics of Chinese Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology HUST, Wuhan, Hubei, China
    PLoS ONE 8:e81657. 2013
  6. doi request reprint STATs in cancer inflammation and immunity: a leading role for STAT3
    Hua Yu
    Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Nat Rev Cancer 9:798-809. 2009

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
    Hua Yu
    Division of Cancer Immunotherapeutics and Tumour Immunology, Beckman Research Institute at the City of Hope National Medical Center, Duarte, California 91010, USA
    Nat Rev Immunol 7:41-51. 2007
    ..Consequently, STAT3 has emerged as a promising target for cancer immunotherapy...
  2. pmc IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway
    Lin Wang
    Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute at City of Hope Medical Center, Duarte, CA 91010, USA
    J Exp Med 206:1457-64. 2009
    ..The Th17 response can thus promote tumor growth, in part via an IL-6-Stat3 pathway...
  3. pmc In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
    Marcin Kortylewski
    Department of Cancer Immunotherapeutics, Beckman Research Institute at City of Hope, Duarte, California, USA
    Nat Biotechnol 27:925-32. 2009
    ..Our findings demonstrate the potential of TLR agonist-siRNA conjugates for targeted gene silencing coupled with TLR stimulation and immune activation in the tumor microenvironment...
  4. pmc STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
    Heehyoung Lee
    Department of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Nat Med 16:1421-8. 2010
    ....
  5. pmc Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma
    Shasha Li
    Genetic Engineering International Cooperation Base of Chinese Ministry of Science and Technology, Key Laboratory of Molecular Biophysics of Chinese Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology HUST, Wuhan, Hubei, China
    PLoS ONE 8:e81657. 2013
    ..Overall, these results suggest that Icaritin strongly inhibits STAT3 activation and is a potentially effective therapeutic option for the treatment of renal cell carcinoma. ..
  6. doi request reprint STATs in cancer inflammation and immunity: a leading role for STAT3
    Hua Yu
    Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA
    Nat Rev Cancer 9:798-809. 2009
    ..Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy...

Research Grants23

  1. Role of Stat3 in modulating tumor microenvironnment and angiogenesis
    HUA E YU; Fiscal Year: 2010
    ..With these and other biological systems and reagents, the proposed studies will define whether Stat3 is an effective target for modulating tumor microenvironment and inhibiting angiogenesis. ..
  2. Stat3 and anti-VEGF therapy in cancer
    Hua Yu; Fiscal Year: 2007
    ..Collectively, these studies may lead to development of more potent VEGF inhibitors for cancer therapy. ..
  3. Targeting Stat3 to Improve Immunotherapy
    HUA E YU; Fiscal Year: 2010
    ....
  4. Stat3 and anti-VEGF therapy in cancer
    Hua Yu; Fiscal Year: 2005
    ..Collectively, these studies may lead to development of more potent VEGF inhibitors for cancer therapy. ..
  5. Immune Responses in Cancer Therapy
    Hua Yu; Fiscal Year: 2005
    ..Finally, we will define the cellular and molecular mechanisms by which innate immune responses triggered by tumor-released pro-inflammatory factors impact on tumor-specific adaptive immune responses. ..
  6. Immune Responses in Cancer Therapy
    Hua Yu; Fiscal Year: 2001
    ..Finally, we will define the cellular and molecular mechanisms by which innate immune responses triggered by tumor-released pro-inflammatory factors impact on tumor-specific adaptive immune responses. ..
  7. Role of Stat3 in modulating tumor microenvironment and angiogenesis
    Hua Yu; Fiscal Year: 2007
    ..With these and other biological systems and reagents, the proposed studies will define whether Stat3 is an effective target for modulating tumor microenvironment and inhibiting angiogenesis. ..
  8. Role of Stat3 in tumor immune evasion and immune suppression
    Hua Yu; Fiscal Year: 2009
    ..If our hypothesis is correct, inhibiting Stat3 in these subsets of immune cells will disrupt the immune suppressive networks, thereby enhancing the efficacy of DC and T-cell based immunotherapies. ..
  9. Role of Stat3 in modulating tumor microenvironment and angiogenesis
    Hua Yu; Fiscal Year: 2009
    ..With these and other biological systems and reagents, the proposed studies will define whether Stat3 is an effective target for modulating tumor microenvironment and inhibiting angiogenesis. ..
  10. Targeting Stat3 to Improve Immunotherapy
    Hua Yu; Fiscal Year: 2009
    ....
  11. Role of Stat3 in tumor immune evasion and immune suppression
    HUA E YU; Fiscal Year: 2010
    ..If our hypothesis is correct, inhibiting Stat3 in these subsets of immune cells will disrupt the immune suppressive networks, thereby enhancing the efficacy of DC and T-cell based immunotherapies. ..
  12. Role of Stat3 in tumor immune evasion and immune suppression
    Hua Yu; Fiscal Year: 2007
    ..If our hypothesis is correct, inhibiting Stat3 in these subsets of immune cells will disrupt the immune suppressive networks, thereby enhancing the efficacy of DC and T-cell based immunotherapies. ..
  13. Role of Stat3 in modulating tumor microenvironnment and angiogenesis
    Hua Yu; Fiscal Year: 2006
    ..With these and other biological systems and reagents, the proposed studies will define whether Stat3 is an effective target for modulating tumor microenvironment and inhibiting angiogenesis. ..
  14. Immune Responses in Cancer Therapy
    Hua Yu; Fiscal Year: 2002
    ..Finally, we will define the cellular and molecular mechanisms by which innate immune responses triggered by tumor-released pro-inflammatory factors impact on tumor-specific adaptive immune responses. ..
  15. Immune Responses in Cancer Therapy
    Hua Yu; Fiscal Year: 2003
    ..Finally, we will define the cellular and molecular mechanisms by which innate immune responses triggered by tumor-released pro-inflammatory factors impact on tumor-specific adaptive immune responses. ..
  16. Stat3 and anti-VEGF therapy in cancer
    Hua Yu; Fiscal Year: 2003
    ..Collectively, these studies may lead to development of more potent VEGF inhibitors for cancer therapy. ..
  17. Stat3 and anti-VEGF therapy in cancer
    Hua Yu; Fiscal Year: 2004
    ..Collectively, these studies may lead to development of more potent VEGF inhibitors for cancer therapy. ..
  18. Immune Responses in Cancer Therapy
    Hua Yu; Fiscal Year: 2004
    ..Finally, we will define the cellular and molecular mechanisms by which innate immune responses triggered by tumor-released pro-inflammatory factors impact on tumor-specific adaptive immune responses. ..
  19. Stat3 and anti-VEGF therapy in cancer
    Hua Yu; Fiscal Year: 2005
    ..Collectively, these studies may lead to development of more potent VEGF inhibitors for cancer therapy. ..
  20. Stat3 and anti-VEGF therapy in cancer
    Hua Yu; Fiscal Year: 2006
    ..Collectively, these studies may lead to development of more potent VEGF inhibitors for cancer therapy. ..
  21. Role of Stat3 in tumor immune evasion and immune suppression
    Hua Yu; Fiscal Year: 2006
    ..If our hypothesis is correct, inhibiting Stat3 in these subsets of immune cells will disrupt the immune suppressive networks, thereby enhancing the efficacy of DC and T-cell based immunotherapies. ..